Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
Retrieved on:
Thursday, July 28, 2022
IBS-D, Degenerative disease, HE, Diarrhea, ANDA, Salix Pharmaceuticals, Court, Electric Bond and Share Company v. Securities and Exchange Commission, Twitter, Dermatology, Global health, United States Court of Appeals for the Federal Circuit, Sun Pharma, Tablet, NYSE, CEO, Bausch Health, Rifaximin, Judgement, Ownership, Gastroenterology, List, Risk, Safety, New Drug Application, BHC, News, Recurrence, Willow, Šolta, FDA, Company, Patient, LinkedIn, Annual report, Neurology, District court, Douglas v. U.S. District Court ex rel Talk America, Form 10-K, Growth, Pharmaceutical industry, Generic drug, Novartis, Teva
LAVAL, Quebec, July 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.
Key Points:
- When the Court enters a final order, Bausch Health will consider all available options to vigorously defend the intellectual property protecting XIFAXAN and will appeal the Court's decision to the U.S. Court of Appeals for the Federal Circuit.
- We strongly disagree with any conclusion that our patents are not valid and intend to file an appeal to any such order," Thomas J. Appio, CEO, Bausch Health, said.
- The Company intends to file an appeal immediately after any final order is issued, assuming it is consistent with the Oral Order.
- Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products.